Neurotransmitters future development

Information processing in the human brain via neuro-chemically defined neuronal systems is complex. Therefore, it remains a challenge to conceptualize psychiatric disorders and their treatment in a reductionistic framework of chemical neuroanatomy. We can nonetheless broadly state that the anatomic organization of neurotransmitter systems determines their behavioral affiliation, and that receptors modulate the electrical or biochemical properties of neurons, with direct relevance to the mechanism of action of psychotropic drugs. Future research will provide more detailed information on the subtypes of neurons and specific neurotransmitters systems that are abnormal in psychiatric disorders, and provide a more rational approach to the development of new treatment interventions. 

Thus, a brief puff of chemical neurotransmission from a presynaptic neuron can trigger a profound postsynaptic reaction, which takes hours to days to develop and can last days to weeks or even longer. Every conceivable component of this entire process of chemical neurotransmission is a candidate for modification by drugs. Most psychotropic drugs act on the processes that control chemical neurotransmission at the level of the neurotransmitters themselves or of their enzymes and especially their receptors. Future psychotropic drugs will undoubtedly act directly on the biochemical cascades, particularly on those elements that control the expression of pre- and postsynaptic genes. Also, mental and neurological illnesses are known or suspected to affect these same aspects of chemical neurotransmission. 

Consequently, antipsychotic drugs all share a basic mechanism of action that involves dopamine receptor blockade. It is apparent, however, that they are not all equal in their ability to affect specific sub-types of dopamine receptors, and that their effectiveness and side effects are related to their affinity and preference for certain receptors. As indicated earlier, other neurotransmitters may also be involved in the pathogenesis of psychosis, and differences in specific antipsychotic medications may be related to their ability to directly or indirectly affect these other transmitters as well as block dopamine influence. Future studies will continue to clarify how current antipsychotics exert their beneficial effects and how new agents can be developed to be more selective in their effects on dopamine and other neurotransmitter pathways. 

The antidepressants available in the United States are classified by either their chemical structure (e.g., the tricyclics, TCAs) or their actions on neurotransmitters (e.g., SSRIs and MAOIs) or simply as other (e.g., Wellbutrin). In the future, the classification of the antidepressants may become more confusing as new drugs are developed that are neither TCAs, SSRIs, or MAOIs. 

In this chapter, we aim to review the techniques used in developing structurally small electrodes of different geometries, which were then applied to the detection of neurotransmitters. We will also pay special emphasis on the strategies used to minimize electrode fouling during electrochemical detection of neurotransmitters at these electrodes. A comparison of these methods and possible future directions in the development of structurally small electrodes for detection of neurotransmitters will also be presented. 

---